GENinCode (LSE:GENI) Research & Development : £0.00 Mil (TTM As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is GENinCode Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. GENinCode's Research & Development for the six months ended in Jun. 2024 was £0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was £0.00 Mil.

GENinCode Research & Development Historical Data

The historical data trend for GENinCode's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GENinCode Research & Development Chart

GENinCode Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

GENinCode Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Research & Development	Get a 7-Day Free Trial					-	-	-	-	-

GENinCode Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

GENinCode (LSE:GENI) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

GENinCode Research & Development Related Terms

Thank you for viewing the detailed overview of GENinCode's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

GENinCode Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

N/A

Address

Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP

Website

https://www.genincode.com

GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment the sale of kits and the provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain, and the United Kingdom.